The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation.
Chimeric Antigen Receptor T cells therapy (CAR-T) has revolutionized the course of disease of patients suffering from Refractory/ Resistant Hematologic malignancies. This success has now lead the FDA and EMA to approve rapidly these innovative cellular drugs.
Based on these unexpected and impressive results, the world of cellular immunotherapy offers new perspectives. The two sessions dedicated to CAR expressing T or NK [Dr Mattias Carlsen] autologous or allogeneic cells [Dr Laurent Poirot] will cover a range of topics from research [Dr Emmanuel Donnadieu (imaging), Dr Suman Mitra (cytokines’ use improvement), Dr Marco Ruella (understanding escape)] to the clinic [Dr Jordan Gauthier, Pr André Baruchel] through drug production [Dr Isabelle Rivière, Dr Georg Rauser].
It will also give another view of the remarkable potential of this approach in solid tumors [Pr Stephan Depil]. It will explain how European Bone Marrow Transplantation registry may help in better understanding Immune Effector Cells derived therapeutics [Pr Christian Chabannon].
Mix and exchanges of people from different backgrounds (academic, scientists, pharmacists, clinicians, private companies…) will provide an excellent platform to help the development of CAR-T cells in France and worldwide in order to propose these innovative drugs to patients.
This session will gather experts in the development of IPS and MSCs cell-based therapies to the clinic. IPs will be discussed as source of hematopoietic cells [Nico Lachmann] or tissues [John de Vos] and MCSs in the context of auto or allo-therapies [Jens Kastrup] or in rheumatoid diseases [Christian Jorgensen].
Speakers will give us feedback on difficulties and successes, and their view on the future of such approaches to ameliorate patients’ care.
This session will give us an overview of the regulatory guidelines defined for ATMP and border-line products [Nicolas Ferry], a review of the last months of work of the ANSM gate dedicated to innovative products [Marc Martin] as well as the European view of ATMP deployment in hematological malignancies [Christian Chabannon]. Also, difficulties and success in the production of such products will be tell with concrete examples by people facing production and regulatory constraints [Hélène Negre-Trebeden; Anne Fialaire-Legendre; Fabienne Pouthier].
Introductive words, Sylvain Perruche, RIGHT Institute, Besançon, FR
Welcome words from the urban community’s President
Welcome words from the Region’s President
Welcome words from the Pôle des Microtechniques’ President
Welcome words from the National French Blood Center’s President
Pierre Tiberghien, EFS, Paris, FR
Chairmen: Christophe Ferrand and Marina Deschamps, RIGHT institute, Besançon, FR
Isabelle Rivière, Memorial Sloan Kettering, NYC, USA
Georg Rauser, Miltenyi Biomedicine, DE
André Baruchel, Hôpital Robert-Debré, Paris, FR
Emmanuel Donnadieu, INSERM, Institut Cochin, Paris, FR
Laurent Poirot, Cellectis, Paris, FR
Chairmen: Marie José Stasia, Grenoble Alpes University, Grenoble, FR
and Sylvain Perruche, RIGHT Institute, Besançon, FR
Christian Jorgensen, INSERM U1183, IRMB, Montpellier, FR
Jens Kastrup, Rigshospitalet, DK
John de Vos, INSERM U1183, IRMB, Montpellier, FR
Nico Lachmann, Hannover Medical School, Hannover, DE
Annelise Bennaceur, INSERM U935 ESTeam, University Paris Saclay, FR
Chairmen: Mathieu Guerriaud, CREDIMI, Dijon, FR
and Pierre Tiberghien, EFS, Paris, FR
Nicolas Ferry, Paris, FR
Hélène Negre-Trebeden, Paris, FR ex-Dana-Farber Cancer Institute
Marc Martin, ANSM, FR
10:30 : PRESENTATION OF THE EFS PHARMACEUTICAL ESTABLISHMENT AND LOCAL SPECIFICITIES
Anne Fialaire-Legendre, EFS, FR & Fabienne Pouthier, EFS BFC, FR
Christian Chabannon, Institut Paoli-Calmettes, Marseille, FR
Chairmen: Eric Deconinck, RIGHT institute, Besançon, FR
and Suman Mitra, INSERM, Lille, FR
Marco Ruella, Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, USA
Suman Mitra, INSERM, Lille, FR
Stephane Depil, Centre Léon Bérard, Lyon, FR
Jordan Gauthier, Fred Hutchinson Cancer Research Center , University of Washington, Seattle, WA, USA
Marcello Maresca, AstraZeneca, Sweden, SW
André Baruchel – Hôpital Robert-Debré (Paris, FR), Annelise Bennaceur, INSERM U935 ESTeam, University Paris Saclay (Paris, FR), Christian Chabannon – Institut Paoli-Calmettes (Marseille, FR), Bruno Dalle, Yposkesi (Corbeille-Essonnes, FR), Stéphane Depil – Centre Léon Bérard (Lyon, FR), John de Vos – INSERM U1183, IRMB (Montpellier, FR), Emmanuel Donnadieu – INSERM, Institut Cochin (Paris, FR), Nicolas Ferry (Paris, FR), Jordan Gauthier – Fred Hutch CR (Seattle, USA), Christian Jorgensen – INSERM U1183, IRMB (Montpellier, FR), Jens Kastrup – Rigshospitalet (DK), Nico Lachmann – Hannover Medical School (Hannover, DE), Marcello Maresca, Astrazeneca (Södertälje, SW), Suman Mitra – INSERM (Lille, FR), Constance Perrot, EASE (Illkirch, FR), Laurent Poirot – Cellectis (Paris, FR), Georg Rauser, Miltenyi Biomedicine (Bergisch Gladbach, DE), Isabelle Rivière – Memorial Sloan Kettering (New-York City, USA), Marco Ruella – Center for Cellular Immunotherapies, U Penn (Philadelphia, USA), Pierre Tiberghien – EFS (Paris, FR)…